We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aubagio

News List

Sanofi’s Aubagio obtains EC approval for paediatric multiple sclerosis pharmaceutical-technology
June 22, 2021
Sanofi has obtained approval from the European Commission (EC) for its Aubagio (teriflunomide) to treat paediatric patients aged ten to 17 years with relapsing-remitting multiple sclerosis (RRMS).
EC approves Ponvory for relapsing MS pharmatimes
May 26, 2021
The European Commission (EC) has cleared Janssen’s Ponvory for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease.
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial pharmatimes
April 20, 2021
New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies biospace
April 24, 2018
Patients with relapsing multiple sclerosis who switched to Sanofi Genzyme's Aubagio® from interferon therapy experienced improvements in treatment satisfaction, according to investigational data from two clinical studies.